Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2019, Article ID 4789101, 7 pages
https://doi.org/10.1155/2019/4789101
Research Article

Biochemical Changes in Blood of Patients with Duchenne Muscular Dystrophy Treated with Granulocyte-Colony Stimulating Factor

1Department of Pediatric Rehabilitation, Medical University of Bialystok, Bialystok, Poland
2Bialystok Technical University, Bialystok, Poland
3Department of Pediatric Radiology, Medical University of Bialystok, Bialystok, Poland

Correspondence should be addressed to Wojciech Kułak; lp.pw@2ruenk

Received 8 December 2018; Revised 10 February 2019; Accepted 14 February 2019; Published 13 March 2019

Academic Editor: Luigia Trabace

Copyright © 2019 Dorota Sienkiewicz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Anderlini and R. E. Champlin, “Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges,” Blood, vol. 111, no. 4, pp. 1767–1772, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Renner, S. Milazzo, JP. Liu, M. Zwahlen, J. Birkmann, and M. Homeber, “Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients,” Cochrane Database of Systematic Reviews, vol. 10, article CD007913, 2012. View at Google Scholar
  3. Y. Zhang, G. Cheng, K. Yang et al., “A novel function of granulocyte colony-stimulating factor in mobilization of human hematopoietic progenitor cells,” Immunology & Cell Biology, vol. 87, no. 5, pp. 428–432, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Schuster, M. Klotz, T. Schwab, R. Lilischkis, A. Schneider, and K. H. Schafer, “Granulocyte-colony stimulating factor: a new player for the enteric nervous system,” Cell and Tissue Research, vol. 355, no. 1, pp. 35–48, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. S. Song, C. H. Fang, B. I. So, J. Y. Park, D. W. Jun, and K. S. Kim, “Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat,” Annals of Hepatology, vol. 12, no. 1, pp. 115–122, 2013. View at Google Scholar
  6. Y. Lee, Y. Song, C. Fang et al., “Anti-obesity effects of granulocyte-colony stimulating factor in otsuka-long-evans-tokushima fatty rats,” PLoS ONE, vol. 9, no. 8, article e105603, 2014. View at Publisher · View at Google Scholar
  7. D. F. Stroncek, M. E. Clay, M. L. Petzoldt et al., “Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells,” Transfusion, vol. 36, no. 7, pp. 601–610, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. K. J. Hatfield, G. K. Melve, and Ø. Bruserud, “Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors,” Metabolomics, vol. 13, no. 1, article 2, 2017. View at Google Scholar · View at Scopus
  9. D. Sienkiewicz, W. Kulak, B. Okurowska-Zawada et al., “Efficacy and the safety of granulocyte colony-stimulating factor treatment in patients with muscular dystrophy: a non-randomized clinical trial,” Frontiers in Neurology, vol. 8, article 566, 2017. View at Google Scholar · View at Scopus
  10. E. Mercuri and F. Muntoni, “Muscular dystrophies,” The Lancet, vol. 381, no. 9869, pp. 845–860, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. J. R. Mendell and M. Lloyd-Puryear, “Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy,” Muscle & Nerve, vol. 48, no. 1, pp. 21–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Braun, Z. Wang, D. L. Mack, and M. K. Childers, “Gene therapy for inherited muscle diseases: where genetics meets rehabilitation medicine,” American Journal of Physical Medicine & Rehabilitation, vol. 93, pp. S97–S107, 2014. View at Publisher · View at Google Scholar
  13. M. Ervasti and K. J. Sonnemann, “Biology of the striated muscle dystrophin-glycoprotein complex,” International Review of Cytology, vol. 265, pp. 191–225, 2008. View at Google Scholar
  14. K. A. Lapidos, R. Kakkar, and E. M. McNally, “The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma,” Circulation Research, vol. 94, no. 8, pp. 1023–1031, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Shimizu-Motohashi and A. Asakura, “Angiogenesis as a novel therapeutic strategy for Duchenne muscular dystrophy through decreased ischemia and increased satellite cells,” Frontiers in Physiology, vol. 5, article 50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Eljaszewicz, D. Sienkiewicz, K. Grubczak et al., “Effect of periodic granulocyte colony-stimulating factor administration on endothelial progenitor cells and different monocyte subsets in pediatric patients with muscular dystrophies,” Stem Cells International, pp. 1–9, 2016. View at Google Scholar · View at Scopus
  17. J. R. Bach and D. Martinez, “Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival,” Respiratory Care, vol. 56, no. 6, pp. 744–750, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. G. F. Simões, S. U. Benitez, and A. L. Oliveira, “Granulocyte colony-stimulating factor (G-CSF) positive effects on muscle fiber degeneration and gait recovery after nerve lesion in MDX mice,” Brain and Behavior, vol. 4, no. 5, pp. 738–753, 2014. View at Publisher · View at Google Scholar
  19. N. Hayashiji, S. Yuasa, Y. Miyagoe-Suzuki et al., “G-CSF supports long-term muscle regeneration in mouse models of muscular dystrophy,” Nature Communications, vol. 6, article 6745, 2015. View at Google Scholar · View at Scopus
  20. M. Pane, R. Scalise, A. Berardinelli et al., “Early neurodevelopmental assessment in Duchenne muscular dystrophy,” Neuromuscular Disorders, vol. 23, pp. 451–455, 2013. View at Google Scholar
  21. F. Muntoni, “The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009,” Neuromuscular Disorders, vol. 20, no. 5, pp. 355–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Ricotti, D. A. Ridout, E. Scott et al., “Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 84, no. 6, pp. 698–705, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Rodríguez-Cruz, O. R. Cruz-Guzmán, R. E. Escobar, and M. López-Alarcón, “Leptin and metabolic syndrome in patients with Duchenne/Becker muscular dystrophy,” Acta Neurologica Scandinavica, vol. 133, no. 4, pp. 253–260, 2016. View at Google Scholar
  24. P. Anderlini, D. Przepiorka, D. Seong et al., “Clinical toxicity and laboratory effects of granulocyte-colony- stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures,” Transfusion, vol. 36, no. 7, pp. 590–595, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Jin, X. Meng, X. Sun et al., “Granulocyte colony-stimulating factor enhances bone marrow mononuclear cell homing to the liver in a mouse model of acute hepatic injury,” Digestive Diseases and Sciences, vol. 55, no. 10, pp. 2805–2813, 2010. View at Publisher · View at Google Scholar
  26. Y. Ji, U. Dahmen, N. Madrahimov, F. Madrahimova, W. Xing, and O. Dirsch, “G-CSF administration in a small-for-size liver model,” Journal of Investigative Surgery, vol. 22, no. 3, pp. 167–177, 2009. View at Publisher · View at Google Scholar
  27. T. Matsumoto, H. Watanabe, T. Ueno et al., “Appropriate doses of granulocyte-colony stimulating factor reduced atherosclerotic plaque formation and increased plaque stability in cholesterol-fed rabbits,” Journal of Atherosclerosis and Thrombosis, vol. 17, no. 1, pp. 84–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. D. Nimer, R. E. Champlin, and D. W. Golde, “Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor,” Journal of the American Medical Association, vol. 260, no. 22, pp. 3297–3300, 1988. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. Watt, N. Dzamko, W. G. Thomas et al., “CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK,” Nature Medicine, vol. 12, no. 5, pp. 541–548, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. U. A. White and J. M. Stephens, “The gpl 30 receptor cytokine family: regulators of adipocyte development and function,” Current Pharmaceutical Design, vol. 17, no. 4, pp. 340–346, 2011. View at Google Scholar
  31. A. R. Moschen, C. Molnar, S. Geiger et al., “Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor a expression,” Gut, vol. 59, no. 9, pp. 1259–1264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Nishiki, F. Hato, N. Kamata et al., “Selective activation of STAT3 in human monocytes stimulated by G-CSF: implication in inhibition of LPS-induced TNF-alpha production,” American Journal of Physiology-Cell Physiology, vol. 286, no. 6, pp. C1302–C1311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Fernández-Formoso, S. Pérez-Sieira, D. González-Touceda, C. Dieguez, and S. Tovar, “Leptin, 20 years of searching for glucose homeostasis,” Life Sciences, vol. 140, Article ID 14301, pp. 4–9, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Yannaki, E. Athanasiou, A. Xagorari et al., “G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs,” Experimental Hematology, vol. 33, no. 1, pp. 108–119, 2005. View at Publisher · View at Google Scholar · View at Scopus